Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : MT1988
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and PK of Multiple Doses of MT1988
Details : MT1988 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 11, 2024
Lead Product(s) : MT1988
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MT1988
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Sponsor : Forster Foundation
Deal Size : $1.2 million
Deal Type : Financing
Monument Therapeutics Secures £1M for Schizophrenia Program Growth
Details : The funding will support the clinical development of MT1988, a novel fixed-dose combination drug for the treatment of cognitive impairment associated with schizophrenia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 15, 2024
Lead Product(s) : MT1988
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Sponsor : Forster Foundation
Deal Size : $1.2 million
Deal Type : Financing
Safety & PK of Single Doses of MT1980
Details : MT1980 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neuroinflammatory Diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 23, 2022
Reset All
